• BIGtoken is the first digital exchange of transparent and verified consumer data, providing subscribers with the ability to own and earn from their own personal data
• BIGtoken’s diverse global subscriber base is experiencing viral growth, reaching nearly 16 million users by mid-August 2019
• SRAX grew its total revenues in Q2 2019 by 53 percent as compared to Q1 2019, and it has officially changed its name as part of its new business strategy

SRAX Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management and distribution technology platform company providing marketers, content owners and consumers with the tools to unlock, amplify and maximize the value of data. Through its blockchain identification graph technology, or BIGtoken platform, SRAX has designed a consumer-powered data marketplace through which people own and sell their data, providing everyone in the internet ecosystem with the ability to be compensated for and control their own data.

Consumer data is valuable not only to the individual, but also to companies seeking to harvest insights and monetize that data into new revenue models, according to a Forbes article highlighting results of PwC’s 22nd Annual Global CEO survey (http://ibn.fm/wWULi). Data is multiplying at a mind-boggling rate, the article states, which means that companies need to unlock the full value of data while also focusing on its secure and ethical use.

Through BIGtoken, consumers are finally allowed to own and monetize their own data. Consumers decide what data is shared, who can buy it and how it’s used, while advertisers reach real, responsive audiences. Consumers finally know how their data is used and advertisers gain ethically sourced, verified consumer data for targeting.

“Through BIGtoken we put data back into the hands of consumers and through our verticals are delivering verified data to brands looking for a competitive edge,” SRAX CEO and Founder Christopher Miglino stated in a news release (http://ibn.fm/0EZhQ).

In a recent study released by the Stanford Graduate School of Business, economics professors Christopher Tonetti and Charles I. Jones found that consumers wanted to preserve private data, but would elect to sell other personal data to many different firms, capitalizing on the value inherent in sharing their data (http://ibn.fm/44Z62).

To date, SRAX has nearly 16 million BIGtoken users worldwide who have opted-in to monetize their personal data. The BIGtoken platform provides consumers, marketers and developers with a comprehensive data-management solution that leads to consumer empowerment and compensation; data verification and authentication; and open-source governance and development, as a recent article explains (http://ibn.fm/50Cl4).

SRAX has made substantial technology advancements through the SRAX IR platform and BIGtoken, Miglino stated in a news release. SRAX reported a 53 percent revenue growth from Q1 2019 to Q2, for the three months ended June 30, 2019 (http://ibn.fm/NHGDF).

“BIGtoken is the leading edge of the new data economy,” Miglino added. “Our global and diverse BIGtoken subscriber base experienced viral growth in April and reached 15.9 million users as of this week. During the third quarter, we began to monetize our BIGtoken users, as we engaged with brands and several marketing agencies.”

Miglino said that SRAX is now focused on increasing scale within certain data segments in specific countries. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. The Yash Birla Group, based in Mumbai, is one of the country’s largest conglomerates, with diversified interests in consumer and industrial products (http://ibn.fm/V5V4P).

“Through building what we predict will be one of the most valuable opt-in data sets in the world, we are well positioned to generate long-term revenue and value for shareholders,” Miglino concluded.

For more information, visit the company’s website at www.SRAX.com

• The company’s CEO discussed NTRR’s strategic acquisition of hemp retail brand Vivis and hemp cultivator J3 Holdings
• Neutra Corp. plans to finish building and lab improvements to J3 Holdings in 2019
• The company’s focus is on CBD as an option to treat types of chronic pain
• CBD sales in the U.S. are projected to exceed $20 billion by 2024

Texas-based Neutra Corp. (OTCQB: NTRR) is expanding into hemp cultivation and purified hemp extract products. Its CEO, Sydney Jim, discussed the company’s operations and objectives in an exclusive interview with NetworkNewsWire (http://ibn.fm/8n9BU). Jim, a former professional tennis player, emphasized the company’s motivation to help the next generation of athletes with pain management. During the interview, he talks about dealing with pain, not only as a former professional athlete but, on an occasion as recent as last year, when he suffered multiple severe injuries and broken bones as a result of an accident.

Jim knows the benefits of hemp-based products first-hand, and CBD may offer an option for treating different types of chronic pain. A study cited by Harvard University showed that CBD applied on the skin could help lower pain and inflammation due to arthritis (http://ibn.fm/F3emW). Other research demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain – two of the most difficult types of chronic pain to treat.

Neutra Corp.’s goal in 2019 is to become vertically involved in the hemp market, from cultivation to formulation of products and distribution for retail sales in an ever-growing market. Leading cannabis researchers BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024, forecasting a 49 percent compound annual growth rate across all distribution channels (http://ibn.fm/qKj7e).

Neutra’s interests go above and beyond profit. “Most of our focus, obviously, is in our quality and potency of our products, because there is a vast difference between very cheap products and quality products,” Jim said in the interview. It takes a lot of time to extract CBD and make sure only the best quality is made available, which is why those particular products are relatively expensive, Neutra Corp.’s CEO added.

Jim also talked about the company’s strategic acquisition of Vivis, a hemp retail brand with which the Neutra CEO has personally worked. Vivis’ extracts are certified by a third-party lab to ensure their quality. Each Vivis product comes with a certificate of analysis as proof of quality, Jim explained.

Neutra Corp. also aims to finish the building and lab improvements of hemp cultivator J3 Holdings, for which the company recently submitted a letter of intent. J3 Holdings owns a lot of land where hemp can be cultivated, as well as a warehouse – assets that are expected to increase Neutra Corp.’s value. In September, Neutra Corp. plans to “finalize the equipment going in there (J3 Holdings) and wrap the financing up to hit the ground running in 2020.”

On a final note, the company’s CEO expressed his hope of bringing Vivis and J3 together to strengthen Neutra’s market infiltration while helping it become a vertically integrated company with both a strong market presence and an established brand that’s known for the superiority of its product and its commitment to quality.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation
• A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner
• Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels

Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States.

The company’s August 22 announcement (http://ibn.fm/Ljt7D) states that its ChrgD+ product is powered by Lexaria’s proprietary DehydraTECH(TM) technology for rapid CBD delivery to the user’s bloodstream within 15 minutes – sometimes as fast as two minutes in lab testing.

The rapid bio-delivery of CBD through DehydraTECH provides an avenue for safer, less conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare.

ChrgD+ has been available in a limited number of retail stores throughout the western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life without having to travel. Limited-time promotional offers and product updates are also available through the site.

Each serving of ChrgD+ weighs just two grams, making it easy for a consumer to carry multiple servings in a shirt pocket or athletic wear while on the go. The multi-spectrum oil-based powder can be poured innocuously into any hot or cold beverage, and every package contains a manufacturing batch code that makes it simple for consumers to browse lab test results for the actual potency of the package’s ingredients (which contain no THC) as part of Lexaria’s push for transparency.

DehydraTECH technology provides the added benefit of gently removing unpleasant cannabis flavors, so ChrgD+ is able to avoid the artificial flavors or sweeteners that other products may use to mask the strong flavors and aromas inherent to hemp oil.

These innovations are examples of Lexaria’s ongoing mission to enhance the “speed of action, flavor and gastro-intestinal delivery of orally-administered products,” particularly those that utilize cannabinoids, nicotine and ibuprofen.

Zenith Global’s industry analysts predict that the U.S. market for cannabis- and hemp-infused drinks will reach more than $1.4 billion by 2024, almost 15-times the 2018 level, as part of an overall trend toward life-enhancing practices that focus on alternatives to traditional medicines and recreational products, including alcoholic beverages and tobacco products (http://ibn.fm/V6ucn).

With the federal legalization of edible cannabis products only a month away in Canada, Lexaria is also preparing to roll out DehydraTECH-licensed products in collaboration with alcohol-free beer, wine and adult format beverage maker Hill Street Beverage Company Inc. (TSX.V: BEER) on a first-time business-to-business (B2B) basis between Canada’s licensed producers and other businesses licensed by Health Canada to make cannabis-infused edibles. The as-yet unnamed new brand will feature processed tetrahydrocannabinol (THC) and/or CBD powder from cannabis or its less chemically psychoactive hemp variant as part of the companies’ efforts to build production in a new market space.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• The U.S. cannabis market is racing along at a 25 percent CAGR
• Nabis Holdings recently issued a letter to shareholders
• The company has appointed an independent director

Based in Vancouver, Canada, Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P) is targeting positive cash flow and strategic assets in the cannabis space, both in the United States and abroad. Nabis already has investments in Arizona, California, Michigan and Washington and is looking to expand its portfolio to include four to five more states in the next three to four months.

Nabis is headed by two industry veterans who exited another firm after receiving one of the largest takeover offers in the North American industry. The team seems set for a repeat performance in the burgeoning legal cannabis market, which is expected to grow at a CAGR of 24.9 percent from 2017 to 2025 (http://ibn.fm/EwZOw). Such growth would swell the market to around $50 billion by 2025.

Nabis is headed by Shay Shnet and Mark Krytiuk, two executives with a proven pedigree in the cannabis space. The pair are co-founders of MPX Bioceutical Corporation, which merged with iAnthus Capital Holdings Inc. (OTCQX: ITHUF) in a deal that valued MPX at C$835 million. Shnet brings 20 years of business experience to Nabis, where he serves as CEO. At MPX Bioceutical, he was vice president of operations and helped build MPX’s portfolio of international cannabis assets. Shnet is adept at sourcing unique opportunities that deal directly with the development, branding, importing, consumer packaging and distribution of a variety of product lines.

Mark Krytiuk is chairman and president of Nabis. Krytiuk garnered five years of experience as the vice president of grow operations for MPX – a position from which he oversaw the production of medical marijuana and pharma-grade products across North America. Krytiuk has been directly involved in the rapid expansion and growth of nine facilities in three different countries, including projects that involved budgets of up to $30 million.

Recently, Nabis issued a letter to shareholders providing a detailed update on the company’s progress and its outlook for the remainder of 2019 and beyond (http://ibn.fm/p9Us8). In Arizona, Nabis has entered into a definitive agreement to acquire 100 percent of the membership units of a fully integrated medical marijuana business licensed under the Arizona Medical Marijuana Act. The acquisition includes a currently operational dispensary that serves 132,000 patients in the Phoenix (Maricopa County) area. This asset has audited 2018 financials of $8.7 million in revenue with gross margins in excess of 50 percent, as well as an estimated $9.0 million in revenue for 2019.

In California, Nabis’ planned acquisition of the Desert Springs dispensary is expected to close in September. This is a positive cash-flow asset that had sales of $5.7 million in 2018 with 47 percent gross margins, and it’s on track for a similar performance in 2019. The city of Desert Hot Springs has approved retail expansion from the current 2,076 square feet to almost double that at 3,977 square feet, resulting in a retail space and production and distribution areas that are all under one roof.

Nabis’ Michigan operations include four retail locations, with two more under definitive agreements set to close in Q4 2019. This retail network will be partially supplied by Nabis’ permitted production and cultivation facility, which will be located in Bangor City, where the company has closed on 22 acres of land. The facility has been granted one production license and 10 cultivation licenses.

In Washington, Nabis has purchased extraction and production equipment in Port Townsend. The company plans to expand the facility to include highly specialized equipment, two new extraction lines, an extraction clean room and a lab facility. As part of that deal, the company acquired licensing rights within Washington state for ‘Chong’s Choice’ brand products, a widely recognized brand in the cannabis space.

In addition, Nabis recently strengthened its board with the appointment of Emmanuel Paul as an independent director (http://ibn.fm/Nawb0). Paul currently serves as CEO of IndusCann Research, a company focused on the research and commercialization of medical cannabis in India. Prior to that, he was the founding partner of Spartan Wellness Corporation, a unique, veteran-focused, health care service provider specializing in prescribing medical cannabis, as well as providing education and ongoing care.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NABIF are available in the company’s newsroom at http://ibn.fm/NABIF

• SGMD is ideally positioned as American farmers seek refuge from the low prices and reduced sales created by the ongoing U.S.-China trade war
• A recent USDA survey reported an almost 400 percent increase in hemp acreage in 2019
• The hemp industry generated more than $1 billion in revenues in 2018, and it is projected to grow to $1.9 billion by 2022

Sugarmade Inc. (OTCQB: SGMD), a supplier of hydroponic and cultivation equipment to growers in the booming industrial hemp sector, is well-positioned to fulfill the needs of farmers who are choosing to cultivate hemp. A thriving hemp market offers farmers higher prices and greater sales, as well as an attractive way to offset the impact of the U.S.-China tariff trade war, and an increase in hemp farming has created a need for hydroponic equipment from companies like Sugarmade (http://ibn.fm/l5CeD).

In the wake of the trade war between the United States and China, hemp has become a refuge for American farmers suffering from the resulting lower prices and sinking sales, as detailed in a recent CannabisNewsWire article (http://ibn.fm/BhGYA). The uncertain trade relationship between the two countries has created an especially strong market for companies such as Sugarmade that are suppliers of equipment to hemp cultivators. This is particularly true in the markets seeing the fastest growth in hemp farming, such as Western Kentucky and Tennessee. SGMD is not in the hemp-cultivation business itself, but it has a business model of supporting and supplying hemp-industry cultivators, among others.

As a hydroponic-systems expert and supplier, Sugarmade is benefiting from the growth in hemp cultivation. According to USDA statistics, some 128,320 acres of hemp have been planted this year, compared to only 27,424 last year, marking a nearly 400 percent increase. The growing demand for hemp biomass, especially in Kentucky, is generating significantly higher prices than other crops.

According to Hemp Business Journal, the hemp market in the United States was projected to reach more than $1 billion in 2018, with growth at an estimated 14.4 percent five-year CAGR to $1.9 billion through 2022 (http://ibn.fm/nlqQs). SGMD is poised to become a “strong pick-and-shovel” provider to the hemp industry.

Based in Monrovia, California (a suburb of Los Angeles), Sugarmade is a hydroponics and cultivation supply company that’s committed to supporting the industrial-hemp sector. In addition, SGMD is a product and brand marketing company with numerous operations, such as packaging and paper goods for diverse industries.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• ETST reported $227,635 in revenue for the quarter ended June 30, 2019, marking a greater than 36 percent hike when compared to $166,891 for the same period in 2018
• The company’s gross profits spiked by more than 90 percent for the three-month period to $113,126, up from $59,409 for the same period in 2018
• ETST grew its revenue while cutting key operating expenses related to R&D, legal and marketing

Earth Science Tech Inc. (OTCQB: ETST), a diverse biotech company focused on the nutraceutical and pharmaceutical fields, reported sharply higher revenue and gross profit for the three months ended June 30, 2019. Notably, the company recorded a higher than 90 percent gain in gross profit for the 2019 period, alongside increased revenue totals and decreased operating expenses (http://ibn.fm/WSgql).

For the quarter, ETST reported sales of $227,635 – a total that is 36.4 percent higher than the $166,891 in revenues for the comparable period in 2018. Additionally, gross profit jumped to $113,126 in the 2019 quarter, from $59,409 for the same quarter in 2018. To achieve that higher gross profit figure, ETST placed emphasis on cutting key operating expenses, including marketing, legal and R&D.

The ETST report detailed those cuts, including dropping R&D expenses to $22,113 as compared to $65,245 for the same period in 2018. The decrease in 2019 is primarily associated with the company moving its Hygee(TM) medical device out of R&D phase and discontinuing CBD patent applications, per a corporate update. Hygee is a revolutionary home kit designed for the detection of sexually transmitted infections, such as chlamydia, in women. The company sees Hygee as empowering women across the globe while setting a new standard in women’s health. The product has already generated excitement among investors. In other efforts to improve its bottom line, ETST has also been taking a hard look at its marketing expenses. By eliminating magazine marketing, the company was able to decrease these costs to $20,623 in the three-month period, down from $29,267 in the comparable period of 2018.

Those revenue and gross profit gains for the quarter came after ETST earlier reported that product sales were $770,635 for its fiscal year ended March 31, 2019, marking a 66.4 percent increase compared to the $463,108 recorded for the same period in 2018. The company was able to maintain a gross profit total of $295,013 and a gross margin of 38.2 percent in 2019, with full-spectrum cannabinoids driving sales. The company also reported that its core customer base grew as a result of the positive response to its V4 product line (http://ibn.fm/0kclZ).

ETST continues to synergize a passion for health and wellness with its premium products. In a July 2019 SEC filing, ETST management explained that its market advantage strategy is “to design and produce CBD-enhanced nutraceutical products for sale to the general public. (The company) intends to create high-grade, CBD-rich hemp oil and other CBD-containing products unique to the current market in the nutraceuticals industry. (It) believes that (its) formulations will set (ETST) apart from competing products for promoting health.”

The company markets a complete line of high-grade hemp-CBD oils, hemp-CBD caps and CBD pet oil products, with its full-spectrum and pure CBD oils utilizing a super-critical CO2, cold-liquid extraction method.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• Helomics is collaborating with the University of Pittsburgh School of Medicine to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. More than 22,000 women are diagnosed with ovarian cancer in the U.S. each year.
• Entered an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations. The treatment market for thyroid cancer is expected to reach $2.1 billion by 2025.
• Skyline Medical has received its first order for four STREAMWAY machines to be sold to local hospitals in India. The Indian healthcare industry is estimated at more than $100 billion, with the nation’s medical device industry valued at more than $6 billion.
• Helomics signed a collaborative research agreement with Pittsburgh-based molecular imaging company, ChemImage, to expand personalized medicine to prostate cancer diagnosis and treatment.
• TumorGenesis and partner 48Hour Discovery received the Alberta Innovates grant for development of novel cancer treatments.

Predictive Oncology Inc. (NASDAQ: POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable development of patient specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY System is the first true, direct-to-train fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. He has owned and managed dental groups in Michigan and currently owns two dental practices there. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• A leading provider of audience-driven business intelligence and marketing solutions
• Flagship SWARM solution applies advanced data science, behavioral science, artificial intelligence, and market research techniques to deliver powerful audience-driven business intelligence that convert opportunities into business success
• Creating shareholder and corporate value through strategic acquisition of profitable solutions providers backed by strong management teams
• Global business intelligence (BI) market forecast to reach $34.3 billion by 2022 at the compound annual growth rate of 11.03%

CloudCommerce Inc. (OTCQB: CLWD) is a leading provider of audience-driven business intelligence and marketing solutions. Together with its wholly owned subsidiaries, CloudCommerce delivers invaluable end-to-end business intelligence and marketing solutions through a range of services and capabilities.

Flagship Solution

SWARM is an end-to-end solution that applies advanced data science, behavioral science, artificial intelligence and market research techniques to deliver powerful audience-driven business intelligence that converts opportunities into business success.

Through marketing, brand perception, customer-relationship management, human-resources management and operational logistics applications, CloudCommerce’s SWARM solution helps businesses determine who to talk to, what to say and how to motivate targeted audiences to take meaningful action.

The Market

Marketers have largely taken a blanket approach to communication. The same messages are often sent across an entire customer audience with little regard for how different groups of people communicate, build communities and develop their purchasing habits. When marketers do segment audiences, they use objective selection criteria such as income, geography, education or purchase history to deduce attitudes or intentions.

However, research shows that motivations and feelings are much more accurate at predicting behavior. The challenge for businesses is that these factors are also the hardest to gather from audience data. CloudCommerce provides that audience-intelligent data through SWARM, its proprietary behavioral-science approach to audience creation and communication. Through SWARM, CloudCommerce helps marketers identify consumer motivations and triggers in order to effectively predict and influence actions. When companies influence action, they can change opinions, gather support, motivate purchases and inspire change.

In a fast-developing global business intelligence market estimated to grow from $16.3 billion in 2016 to $34.3 billion by 2022, CloudCommerce stands apart as an innovator and true partner, able to deliver data-driven intelligence and solutions that enable its customers to strengthen their brands, deliver their messages and reach their goals.

SWARM Products

THE SWARM—Intelligent Audience Building
The core of the CloudCommerce solution – and what separates CloudCommerce from other audience data companies – is the company’s unique approach to audience building. The concept of “personas” has been around for decades, but CloudCommerce takes that concept to the next level. The SWARM was developed to identify not only who to talk to but also what to say in order to motivate target audiences to take meaningful action. Using CloudCommerce’s proprietary clustering and behavioral analysis techniques, businesses can identify target audiences and deliver messages that are more focused and efficient. CloudCommerce not only helps its client partners find the right people to talk to but also identifies the most powerful message to send.

BUZZ—Behavior-Based Market Research
Market research is evolving. Research techniques developed and used today are more sophisticated and backed by strong data science. Despite these changes, many traditional research firms have failed to innovate: small sample sizes, survey design bias, improper weighting and gut-intuition sampling are just some of the issues that plague the market-research industry. Through BUZZ, CloudCommerce has automated the market research process to provide a level of statistical depth beyond what traditional firms can offer. BUZZ offers businesses the ability to put their finger on the pulse of the marketplace in the moment. Using a wide range of internal and external data sources such as customer data, social media activity, and micro and macro trends, BUZZ deduces attitudes, emotions and opinions.

HIVE—Redefined Geographic Targeting
Conventional geographic audience targeting is outdated. Arbitrary units of location such as counties, cities, DMAs and regions were created centuries ago based on land-rights ownership. Their use in understanding people’s behavior, purchase habits and underlying values is minimal. CloudCommerce has found a much more powerful, efficient and effective way of targeting by clustering people into granular geographic tribes called HIVES. HIVES are defined by attributes such as common language (e.g., colloquialisms), shared experience and narratives (e.g., climate, history), and concentrated demography and biology (e.g., ethnicity, age). Based on the needs of its clients, CloudCommerce can completely redraw the geographic lines based on various Hive selection criteria. Using this exclusive HIVE approach, CloudCommerce clients experience more efficient and effective marketing, make more intelligent business decisions and enjoy more growth.

HONEY—Advanced Reporting and Visualization
Advanced-audience, data-analysis technologies are useless if they don’t produce simple, powerful and actionable business intelligence. HONEY comes with user-friendly reporting and visualization tools to organize and explain all of the advance-data science into a simple-to-understand format for decision makers. HONEY combines the intelligence of client CRM data with third-party consumer data and targeted market research to create a powerful foundation for any audience-intelligence solution.

Subsidiaries

Data Propria
Data Propria delivers the highest Return on Investment (“ROI”) for their customers’ digital marketing campaigns, by utilizing sophisticated data science to identify the correct universes to target relevant audiences. Their ability to understand and translate data drives every decision they make. By listening to and analyzing their customers’ data they are able to make informed decisions that positively impact their customers’ business. Data Propria leverages industry-best tools to aggregate and visualize data across multiple sources, and then their data and behavioral scientists segment and model that data to be deployed in targeted marketing campaigns. They have data analytics expertise in retail, wholesale, distribution, logistics, manufacturing, political, and several other industries.

Parscale Digital
Parscale Digital helps their customers get their message out, educate their market and tell their story. They do so creatively and effectively by deploying powerful call-to-action digital campaigns with national reach and boosting exposure and validation with coordinated advertising in print media. Parscale Digital’s fully-developed marketing plans are founded on sound research methodologies, brand audits and exploration of the competitive landscape. Whether their customer is a challenger brand, a political candidate, or a well-known household name, Parscale Digital’s strategists are skilled at leveraging data and creating campaigns that move people to make decisions.

Giles Design Bureau
Giles Design Bureau approaches branding from a “big picture” perspective, establishing a strong identity and then building on that to develop a comprehensive branding program that tells the customer’s story, and articulates what sets the customer apart from their competitors and establishes the customer in their market.

WebTegrity
WebTegrity develops commerce-focused, user-friendly digital websites and apps that elevate their customer’s marketing position and draw consumers to their products and services. Their platform-agnostic approach allows WebTegrity to architect and build solutions that are the best fit for each customer. Once the digital properties are built, their experts will help manage and protect the website or app and provide the expertise needed to scale the infrastructure needed as the customer’s business grows.

Leadership

Andrew Van Noy, CEO & Chairman of CloudCommerce Board of Directors
Andrew Van Noy has been a director of CloudCommerce since November 2012, president of the company since April 2012, and the CEO of the company since August 2012. He also served as executive vice president of CloudCommerce from November 2011 to April 2012 and vice president of Sales and Marketing of the company from May 2011 to November 2011. From January 2009 to April 2011, Van Noy served as the vice president of Sales and Marketing for PageTransformer, which provided web and software development for iPad, iPhone and Android devices. Van Noy came to CloudCommerce with experience in digital marketing, private equity and investment banking. During his years at the company, Van Noy led the efforts to rebrand and restructure the business and presided over the acquisition of a number of companies. Van Noy graduated from BYU with a Bachelor of Science degree.

Gregory Boden, CFO and Board of Directors
Gregory Boden became a director at CloudCommerce in November 2011 and in February 2013 was named corporate secretary. In April 2012, Boden was also appointed CFO. In addition, Boden is the managing partner of a private equity company. Prior to joining the CloudCommerce team, Boden managed the franchise accounting and cash application departments of Select Staffing, a nationwide staffing company and was an accountant at KPMG LLP. Boden earned his master of accountancy degree from the University of Denver.

Brad Parscale, Board of Directors
Brad Parscale creates web-marketing strategies and oversees all technical and functional aspects of these strategies. Originally from Kansas, Parscale spent five years in California before moving to San Antonio in 2004 to establish Parscale Media, a successful web-marketing firm. His 2011 partnership with Jill Giles formed Giles-Parscale Inc. In 2016, Parscale was named digital director for the Donald J. Trump presidential campaign.

Zachary Bartlett, VP of Corporate Development and Board of Directors
Zachary Bartlett has been a director of the company since July 2012 and was appointed vice president of Corporate Development in January 2018. Bartlett has also served as vice president of Communications and an independent contractor assisting with project management matters. Prior to joining CloudCommerce, Bartlett was the creative director at Crowbar Studios Inc., a graphic design and web development firm he founded in 2008. From 2004 to 2008, he held the position of art and brand consultant at Demon International, a snowboard accessories company. Bartlett earned his bachelor of fine arts degree in graphic design from Brigham Young University.

For more information, visit the company’s website at www.CloudCommerce.com

NOTE TO INVESTORS: The latest news and updates relating to CLWD are available in the company’s newsroom at http://ibn.fm/CLWD

• The direct-selling industry is seeing rapid global growth with the ongoing shift toward a gig economy
• Sharing Services aims to empower independent business leaders to take charge of their own lives while creating record-breaking sales
• The company’s products utilizing dopamine, oxytocin, serotonin and endorphins create elevated happiness levels and are well-received by the market

The direct-selling industry has seen rapid growth globally. Estimated retail sales in 2018 marked a 1.2 percent increase over the previous year, bringing in $192.9 billion (http://ibn.fm/V16x9). More and more people are relying on gig jobs that allow them to avoid long commutes to the office, restricted work hours and bosses. Sharing Services Global Corporation (OTCQB: SHRG) is one of many companies making these conveniences possible in this emerging gig economy, but SHRG stands apart from the others due to its commitment to thoroughly empowering the home-based entrepreneur.

The company calls its independent distributors ‘Elepreneurs’, and it is reshaping the industry by providing necessary tools that can lead individuals to success. From its headquarters in Plano, Texas, the company provides Elepreneurs with quality training, products and services. All of the company’s sales are through organic growth, which is attributed to the Elepreneurs, who are effectively following the company’s Blue Ocean Strategy. Since 2017, the company has added thousands of independent distributors and continues to see growth.

Elepreneurs are focused on elevating their own lives and the lives of customers through products and services. By empowering entrepreneurs to take the reins of their own lives, Sharing Services has created a simpler, more inventive approach to sales and marketing that harnesses the power of relationship marketing. Today’s consumers are reached through cost-effective and personal approaches that other organizations have lacked the ability to accommodate. SHRG Elepreneurs are taught how to connect with others, utilize social media tools and grow organic friendships through excellent customer service. These skills in utilizing customers’ online presence to cultivate personal connections are setting Elepreneurs LLC apart from other direct-selling companies.

SHRG also has a competitive advantage as it taps into the health and wellness market. Wellness products make up an estimated 33.8 percent of America’s direct-selling industry. Synergizing the customer service talents of Elepreneurs with SHRG’s happiness-stimulating products, the company has been able to increase its products’ market penetration.

These products, which are designed to elevate the happiness and well-being of customers, have been created through SHRG’s wholly owned subsidiary, Elevacity LLC. The brand is made up of core products in the nutritional category, including supplements that incorporate the company’s formulation of dopamine, oxytocin, serotonin and endorphins, or D.O.S.E. These four hormones have been shown to promote well-being and happiness.

Backed by scientific data and well-known happiness researcher Shawn Achor (http://ibn.fm/yeP5F), the D.O.S.E. products have been well received and are a large reason for SHRG’s record-breaking sales since the products debuted in December 2017. Whether customers start their day with a D.O.S.E. of happiness mixed with their coffee or in a supplement, they know they are using a product that’s made with the highest standards.

SHRG seems to have found its niche as it focuses on creating products and services that impact the happiness of customers, entrepreneurs and investors alike.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• The company recently completed clinical trials for its acute pain formulation, CTL-X, which is the most advanced product in the Veritas pipeline
• Veritas Pharma works in two directions to put together effective cannabis-based treatments for various medical conditions
• With the help of R&D partner Cannevert Therapeutics, Veritas is developing solutions for various additional issues like chronic pain and sleep disorders

Pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is on a mission to develop the most effective proprietary cannabis strains and products for the treatment of various medical conditions. The company focuses on providing both physicians and patients with conclusive evidence for the recommendation of medical marijuana.

In the spring of 2019, Veritas announced the results of its product clinical trials in support of the company’s commitment to developing the most effective products (http://ibn.fm/dgy4C). The cannabis treatment clinical trial (randomized, double-blinded, cross-over) tested the effectiveness of the company’s vaporized CTL-X acute pain product. Studies were carried out following GMP standards over the course of three months. The results provide real scientific evidence of the use of cannabis for medical purposes and, more specifically, for the treatment of acute pain.

“We believe that for millions of people suffering from acute pain vaporized cannabis can potentially reduce the need for other medications, including opioids. From results of this study, clinicians will have a better understanding for specific dosage and delivery of cannabis for acute pain,” Veritas Medical Director Dr. Scott Alexander stated in a news release.

Veritas’ innovative research and development approach aims to solve the critical need for scientific research to support claims about the effectiveness of cannabis-based treatments. Through its research and development subsidiary, Cannevert Therapeutics Ltd., Veritas is developing innovative products for the treatment of various medical conditions like chronic and acute pain, sleep disorders and palliative care.

Cannevert has screened numerous cannabis strains to pinpoint their potential in treating chronic pain and reducing the need for opioid administration. Acute pain treatment CTL-X is the most advanced product in the Veritas pipeline and therefore the focus of its clinical trial efforts.

Veritas is also concerned with sleep disorders and the growing prominence of the conditions. Studies show that Americans are now getting one to two hours less sleep than previous generations (http://ibn.fm/yIp3V). In 1942, only 11 percent of Americans slept six hours or less per night. By 2013, the number had increased to 40 percent of the adult population, the American Association of Retired Persons (AARP) reported.

Through its research, Veritas is attempting to identify cannabis as a reliable solution to this growing problem. There is some anecdotal evidence, and Cannevert is working to develop biological assays to identify the most effective strain for the treatment of insomnia, parasomnia, chronic fatigue syndrome and others.

Based at the University of British Columbia, Cannevert has brought together a team of pharmacologists, chemists and anesthetists who have substantial prior experience in drug development. Through the partnership, Veritas gains the technical ability to achieve its effective treatment development vision.

For more information, visit the company’s website at www.VeritasPharmaInc.com